Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of “Buy” by Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been assigned a consensus recommendation of “Buy” from the twelve ratings firms that are covering the firm, MarketBeat Ratings reports. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $57.73.

MIRM has been the subject of a number of recent analyst reports. Leerink Partners boosted their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Citigroup boosted their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Robert W. Baird raised their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Cantor Fitzgerald boosted their price objective on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Finally, Evercore ISI raised their target price on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,500 shares of the company’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $47.10, for a total value of $117,750.00. Following the completion of the transaction, the senior vice president now directly owns 2,426 shares in the company, valued at approximately $114,264.60. This represents a 50.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.87% of the stock is owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Quest Partners LLC increased its stake in shares of Mirum Pharmaceuticals by 7,513.3% during the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after purchasing an additional 1,127 shares in the last quarter. Amalgamated Bank raised its stake in Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after buying an additional 513 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after buying an additional 318 shares during the last quarter. ProShare Advisors LLC bought a new stake in Mirum Pharmaceuticals in the second quarter worth $213,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Mirum Pharmaceuticals in the third quarter worth $215,000.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $44.73 on Wednesday. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -22.14 and a beta of 1.16. Mirum Pharmaceuticals has a 52-week low of $23.14 and a 52-week high of $48.89. The stock’s 50-day simple moving average is $40.29 and its 200 day simple moving average is $36.76.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. The company had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. Mirum Pharmaceuticals’s revenue was up 89.4% compared to the same quarter last year. During the same period last year, the business earned ($0.57) earnings per share. Research analysts forecast that Mirum Pharmaceuticals will post -1.48 EPS for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.